MicroRNA-381 reduces inflammation and infiltration of macrophages in polymyositis via downregulating HMGB1

Liu,Yutao; Gao,Yuan; Yang,Jing; Shi,Changhe; Wang,Yanlin; Xu,Yuming

doi:10.3892/ijo.2018.4463

MicroRNA-381 reduces inflammation and infiltration of macrophages in polymyositis via downregulating HMGB1

Authors:
- Yutao Liu
- Yuan Gao
- Jing Yang
- Changhe Shi
- Yanlin Wang
- Yuming Xu
View Affiliations

Affiliations: Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China
Published online on: June 29, 2018 https://doi.org/10.3892/ijo.2018.4463
Pages: 1332-1342

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The downregulation of microRNA (miR)-381 has been detected in various diseases. The present study aimed to investigate the effects, and underlying mechanisms of miR-381 on inflammation and macrophage infiltration in polymyositis (PM). A mouse model of experimental autoimmune myositis (EAM) was generated in this study. Hematoxylin and eosin staining was conducted to detect the inflammation of muscle tissues. In addition, ELISA and immunohistochemistry were performed to determine the expression levels of associated factors, and reverse transcription-quantitative polymerase chain reaction and western blotting were used to detect the expression levels of related mRNAs and proteins. A luciferase activity assay was used to confirm the binding of miR-381 and high mobility group box 1 (HMGB1) 3' untranslated region. Transwell assays were also performed to assess the migratory ability of macrophages. The results demonstrated that serum creatine kinase (s-CK), HMGB1 and cluster of differentiation (CD)163 expression in patients with PM were increased compared within healthy controls. Conversely, the expression levels of miR-381 were downregulated in patients with PM. Furthermore, high HMGB1 expression was associated with poor survival rate in patients with PM. In the mouse studies, muscle inflammation and CD163 expression were decreased in the anti-IL-17 and anti-HMGB1 groups, compared with in the EAM model group. The expression levels of s-CK, HMGB1, IL-17 and intercellular adhesion molecule (ICAM)-1 were also downregulated in response to anti-IL-17 and anti-HMGB1. These findings indicated that HMGB1 was closely associated with inflammatory responses. In addition, the present study indicated that transfection of macrophages with miR-381 mimics reduced the migration of inflammatory macrophages, and the expression levels of HMGB1, IL-17 and ICAM-1. Conversely, miR-381 inhibition exerted the opposite effects. The effects of miR-381 inhibitors were reversed by HMGB1 small interfering RNA. In conclusion, miR-381 may reduce inflammation and the infiltration of macrophages; these effects were closely associated with the downregulation of HMGB1.

View Figures

View References

1	Maoz CR, Langevitz P, Livneh A, Blumstein Z, Sadeh M, Bank I, Gur H and Ehrenfeld M: High incidence of malignancies in patients with dermatomyositis and polymyositis: An 11-year analysis. Semin Arthritis Rheum. 27:319–324. 1998. View Article : Google Scholar : PubMed/NCBI
2	Wang J, Guo G, Chen G, Wu B, Lu L and Bao L: Meta-analysis of the association of dermatomyositis and polymyositis with cancer. Br J Dermatol. 169:838–847. 2013. View Article : Google Scholar : PubMed/NCBI
3	Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, Evans SR and Felson DT: Frequency of specific cancer types in dermatomyositis and polymyositis: A population-based study. Lancet. 357:96–100. 2001. View Article : Google Scholar : PubMed/NCBI
4	Rayavarapu S, Coley W and Nagaraju K: An update on pathogenic mechanisms of inflammatory myopathies. Curr Opin Rheumatol. 23:579–584. 2011. View Article : Google Scholar : PubMed/NCBI
5	Fasth AE, Dastmalchi M, Rahbar A, Salomonsson S, Pandya JM, Lindroos E, Nennesmo I, Malmberg KJ, Soderberg-Naucler C, Trollmo C, et al: T cell infiltrates in the muscles of patients with dermatomyositis and polymyositis are dominated by CD28null T cells. Journal of immunology (Baltimore, Md : 1950). 183:4792–4799. 2009. View Article : Google Scholar
6	Henriques-Pons A and Nagaraju K: Nonimmune mechanisms of muscle damage in myositis: Role of the endoplasmic reticulum stress response and autophagy in the disease pathogenesis. Curr Opin Rheumatol. 21:581–587. 2009. View Article : Google Scholar : PubMed/NCBI
7	Salajegheh M, Kong SW, Pinkus JL, Walsh RJ, Liao A, Nazareno R, Amato AA, Krastins B, Morehouse C, Higgs BW, et al: Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy. Ann Neurol. 67:53–63. 2010. View Article : Google Scholar : PubMed/NCBI
8	Walsh RJ, Kong SW, Yao Y, Jallal B, Kiener PA, Pinkus JL, Beggs AH, Amato AA and Greenberg SA: Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum. 56:3784–3792. 2007. View Article : Google Scholar : PubMed/NCBI
9	Wenzel J, Scheler M, Bieber T and Tüting T: Evidence for a role of type I interferons in the pathogenesis of dermatomyositis. Br J Dermatol. 153:462–463; author reply 463–464. 2005. View Article : Google Scholar : PubMed/NCBI
10	Scovell WM: High mobility group protein 1: A collaborator in nucleosome dynamics and estrogen-responsive gene expression. World J Biol Chem. 7:206–222. 2016. View Article : Google Scholar : PubMed/NCBI
11	Musumeci D, Roviello GN and Montesarchio D: An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies. Pharmacol Ther. 141:347–357. 2014. View Article : Google Scholar
12	Yang Q, Liu X, Yao Z, Mao S, Wei Q and Chang Y: Penehyclidine hydrochloride inhibits the release of high-mobility group box 1 in lipopolysaccharide-activated RAW264.7 cells and cecal ligation and puncture-induced septic mice. J Surg Res. 186:310–317. 2014. View Article : Google Scholar
13	Harris HE, Andersson U and Pisetsky DS: HMGB1: A multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol. 8:195–202. 2012. View Article : Google Scholar : PubMed/NCBI
14	Lotze MT and Tracey KJ: High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat Rev Immunol. 5:331–342. 2005. View Article : Google Scholar : PubMed/NCBI
15	Pisetsky DS, Erlandsson-Harris H and Andersson U: High-mobility group box protein 1 (HMGB1): An alarmin mediating the pathogenesis of rheumatic disease. Arthritis Res Ther. 10:2092008. View Article : Google Scholar : PubMed/NCBI
16	Müller S, Scaffidi P, Degryse B, Bonaldi T, Ronfani L, Agresti A, Beltrame M and Bianchi ME: New EMBO members' review: The double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J. 20:4337–4340. 2001. View Article : Google Scholar : PubMed/NCBI
17	Moestrup SK and Møller HJ: CD163: A regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. Ann Med. 36:347–354. 2004. View Article : Google Scholar : PubMed/NCBI
18	Niimoto T, Nakasa T, Ishikawa M, Okuhara A, Izumi B, Deie M, Suzuki O, Adachi N and Ochi M: MicroRNA-146a expresses in interleukin-17 producing T cells in rheumatoid arthritis patients. BMC Musculoskelet Disord. 11:2092010. View Article : Google Scholar : PubMed/NCBI
19	Hirota K, Hashimoto M, Yoshitomi H, Tanaka S, Nomura T, Yamaguchi T, Iwakura Y, Sakaguchi N and Sakaguchi S: T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17⁺ Th cells that cause autoimmune arthritis. J Exp Med. 204:41–47. 2007. View Article : Google Scholar : PubMed/NCBI
20	Lee YK, Mukasa R, Hatton RD and Weaver CT: Developmental plasticity of Th17 and Treg cells. Curr Opin Immunol. 21:274–280. 2009. View Article : Google Scholar : PubMed/NCBI
21	Crispin JC, Oukka M, Bayliss G, Cohen RA, Van Beek CA, Stillman IE, Kyttaris VC, Juang YT and Tsokos GC: Expanded double negative T cells in patients with systemic lupus erythe-matosus produce IL-17 and infiltrate the kidneys. J Immunol. 181:8761–8766. 2008. View Article : Google Scholar
22	Pickens SR, Volin MV, Mandelin AM 2nd, Kolls JK, Pope RM and Shahrara S: IL-17 contributes to angiogenesis in rheumatoid arthritis. J Immunol. 184:3233–3241. 2010. View Article : Google Scholar : PubMed/NCBI
23	Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan T, Kastelein RA and Cua DJ: IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 201:233–240. 2005. View Article : Google Scholar : PubMed/NCBI
24	Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM and Fugger L: Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol. 172:146–155. 2008. View Article : Google Scholar :
25	Gao Q, Jiang Y, Ma T, Zhu F, Gao F, Zhang P, Guo C, Wang Q, Wang X, Ma C, et al: A critical function of Th17 proinflam-matory cells in the development of atherosclerotic plaque in mice. J Immunol. 185:5820–5827. 2010. View Article : Google Scholar : PubMed/NCBI
26	Smith E, Prasad KM, Butcher M, Dobrian A, Kolls JK, Ley K and Galkina E: Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation. 121:1746–1755. 2010. View Article : Google Scholar : PubMed/NCBI
27	Othumpangat S, Noti JD, McMillen CM and Beezhold DH: ICAM-1 regulates the survival of influenza virus in lung epithelial cells during the early stages of infection. Virology. 487:85–94. 2016. View Article : Google Scholar :
28	Gabr MA, Jing L, Helbling AR, Sinclair SM, Allen KD, Shamji MF, Richardson WJ, Fitch RD, Setton LA and Chen J: Interleukin-17 synergizes with IFNgamma or TNFalpha to promote inflammatory mediator release and intercellular adhesion molecule-1 (ICAM-1) expression in human interver-tebral disc cells. J Orthop Res. 29:1–7. 2011. View Article : Google Scholar
29	Plaisance-Bonstaff K and Renne R: Viral miRNAs. Methods Mol Biol. 721:43–66. 2011. View Article : Google Scholar : PubMed/NCBI
30	Huang J, Zhang SY, Gao YM, Liu YF, Liu YB, Zhao ZG and Yang K: MicroRNAs as oncogenes or tumour suppressors in oesophageal cancer: Potential biomarkers and therapeutic targets. Cell Prolif. 47:277–286. 2014. View Article : Google Scholar : PubMed/NCBI
31	Li J, You T and Jing J: MiR-125b inhibits cell biological progression of Ewing's sarcoma by suppressing the PI3K/Akt signalling pathway. Cell Prolif. 47:152–160. 2014. View Article : Google Scholar : PubMed/NCBI
32	Li M, Yu M, Liu C, Zhu H, He X, Peng S and Hua J: miR-34c works downstream of p53 leading to dairy goat male germline stem-cell (mGSCs) apoptosis. Cell Prolif. 46:223–231. 2013. View Article : Google Scholar : PubMed/NCBI
33	Li Z, Yu X, Shen J and Jiang Y: MicroRNA dysregulation in uveal melanoma: A new player enters the game. Oncotarget. 6:4562–4568. 2015.PubMed/NCBI
34	Xu Z, Asahchop EL, Branton WG, Gelman BB, Power C and Hobman TC: MicroRNAs upregulated during HIV infection target peroxisome biogenesis factors: Implications for virus biology, disease mechanisms and neuropathology. PLoS Pathog. 13:e10063602017. View Article : Google Scholar : PubMed/NCBI
35	Cao Q, Liu F, Ji K, Liu N, He Y, Zhang W and Wang L: MicroRNA-381 inhibits the metastasis of gastric cancer by targeting TMEM16A expression. J Exp Clin Cancer Res. 36:292017. View Article : Google Scholar : PubMed/NCBI
36	Hou C, Meng F, Zhang Z, Kang Y, Chen W, Huang G, Fu M, Sheng P, Zhang Z and Liao W: The role of MicroRNA-381 in chondrogenesis and interleukin-1-beta induced chondrocyte responses. Cell Physiol Biochem. 36:1753–1766. 2015. View Article : Google Scholar
37	Zhang X, Goncalves R and Mosser DM: The isolation and characterization of murine macrophages. Curr Protoc Immunol Chapter 14. Unit. 14:12008.
38	Arahata K and Engel AG: Monoclonal antibody analysis of mono-nuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol. 16:193–208. 1984. View Article : Google Scholar : PubMed/NCBI
39	Engel AG and Arahata K: Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol. 16:209–215. 1984. View Article : Google Scholar : PubMed/NCBI
40	Goebels N, Michaelis D, Engelhardt M, Huber S, Bender A, Pongratz D, Johnson MA, Wekerle H, Tschopp J, Jenne D, et al: Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis. J Clin Invest. 97:2905–2910. 1996. View Article : Google Scholar : PubMed/NCBI
41	Zong M and Lundberg IE: Pathogenesis, classification and treatment of inflammatory myopathies. Nat Rev Rheumatol. 7:297–306. 2011. View Article : Google Scholar : PubMed/NCBI
42	Notarnicola A, Lapadula G, Natuzzi D, Lundberg IE and Iannone F: Correlation between serum levels of IL-15 and IL-17 in patients with idiopathic inflammatory myopathies. Scand J Rheumatol. 44:224–228. 2015. View Article : Google Scholar
43	Yin Y, Li F, Shi J, Li S, Cai J and Jiang Y: MiR-146a regulates inflammatory infiltration by macrophages in polymyositis/derma-tomyositis by targeting TRAF6 and affecting IL-17/ICAM-1 pathway. Cell Physiol Biochem. 40:486–498. 2016. View Article : Google Scholar
44	Miossec P: Interleukin-17 in fashion, at last: Ten years after its description, its cellular source has been identified. Arthritis Rheum. 56:2111–2115. 2007. View Article : Google Scholar : PubMed/NCBI
45	Kenna TJ and Brown MA: The role of IL-17-secreting mast cells in inflammatory joint disease. Nat Rev Rheumatol. 9:375–379. 2013. View Article : Google Scholar
46	Baeten DL and Kuchroo VK: How Cytokine networks fuel inflammation: Interleukin-17 and a tale of two autoimmune diseases. Nat Med. 19:824–825. 2013. View Article : Google Scholar : PubMed/NCBI
47	Sallum AM, Kiss MH, Silva CA, Wakamatsu A, Vianna MA, Sachetti S and Marie SK: Difference in adhesion molecule expression (ICAM-1 and VCAM-1) in juvenile and adult dermatomyositis, polymyositis and inclusion body myositis. Autoimmun Rev. 5:93–100. 2006. View Article : Google Scholar : PubMed/NCBI
48	Szodoray P, Alex P, Knowlton N, Centola M, Dozmorov I, Csipo I, Nagy AT, Constantin T, Ponyi A, Nakken B, et al: Idiopathic inflammatory myopathies, signified by distinctive peripheral cytokines, chemokines and the TNF family members B-cell activating factor and a proliferation inducing ligand. Rheumatology (Oxford). 49:1867–1877. 2010. View Article : Google Scholar
49	Tournadre A, Porcherot M, Chérin P, Marie I, Hachulla E and Miossec P: Th1 and Th17 balance in inflammatory myopathies: Interaction with dendritic cells and possible link with response to high-dose immunoglobulins. Cytokine. 46:297–301. 2009. View Article : Google Scholar : PubMed/NCBI
50	Yin Y, Li F, Shi J, Li S, Cai J and Jiang Y: MiR-146a regulates inflammatory infiltration by macrophages in polymyositis/derma-tomyositis by targeting TRAF6 and affecting IL-17/ICAM-1 Pathway. Cell Physiol Biochem. 40:486–498. 2016. View Article : Google Scholar
51	Tang Q, Li J, Zhu H, Li P, Zou Z and Xiao Y: Hmgb1-IL-23-IL-17-IL-6-Stat3 axis promotes tumor growth in murine models of melanoma. Mediators Inflamm. 2013:7138592013. View Article : Google Scholar